Overview

Early Post-marketing Study of Eliquis (Apixaban)

Status:
Withdrawn
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to identify and describe any suspected (AEs) in all patients with NVAF treated with Apixaban, as a request of the National Center of Pharmacovigilance (CNFV) in Mexico.
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Apixaban